Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AmpliPhi Adds Two Board Members

This article was originally published in Scrip

Executive Summary

AmpliPhi Biosciences Corp. has appointed Vijay B. Samant and Paul C. Grint to its board as non-executive directors. Samant is currently president and CEO of Vical, Inc and prior to this he held various positions at Merck & Co. He was CEO of the Merck Vaccine Division, vice president (VP) of vaccine operations, VP of business affairs and director of materials management. Samant also served on the board of various companies including Raptor Pharmaceuticals and BioMarin. Grint is president and CEO of Regulus Therapeutics Inc. and before this he was president of Cerexa Inc. Previously he served in senior management roles at Forest Research Institute, Pfizer and IDEC Pharmaceuticals.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts